Antibodies Licensed From Trellis Bring MedImmune More Potential RSV Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
Using very high throughput screening, Trellis identified antibodies in human blood that had been selected by the immune system to fight the virus.
You may also be interested in...
AstraZeneca's MedImmune Comes Closer To Motavizumab Approval, And A Tight Grip On RSV Market
AstraZeneca's biologics unit MedImmune is continuing to solidify its domination of the market for products to prevent serious respiratory syncytial virus disease in high-risk infants with a formal reply to FDA's "complete response" letter for its investigational product motavizumab
AstraZeneca's MedImmune Comes Closer To Motavizumab Approval, And A Tight Grip On RSV Market
AstraZeneca's biologics unit MedImmune is continuing to solidify its domination of the market for products to prevent serious respiratory syncytial virus disease in high-risk infants with a formal reply to FDA's "complete response" letter for its investigational product motavizumab
Deals Of The Week: Pfizer/Protalix, AstraZeneca/Targacept, Chiesi/Phenomix
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.